Fierce Biotech1 min read
saveBristol Myers Squibb leads $237 million Series E for Pathos AI and launches Alzheimer's collaboration
read at Fierce Biotech ↗DealPositive
Bristol Myers Squibb (BMS) headed a financing round that raised $237 million for biotech Pathos AI.
The Series E funding will support Pathos AI's development of its AI‑driven platform for drug discovery.
At the same time, BMS and Pathos AI announced a partnership focused on discovering new treatments for Alzheimer's disease.
The collaboration combines BMS's clinical expertise with Pathos AI's computational tools to accelerate target identification.
source
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “BMS leads Pathos AI's $237M series E alongside Alzheimer's link-up”
read at Fierce Biotech ↗427 words · retrieved 3d ago
comments(0)
5-min edit window · permanent after that